Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages

Annals of the Rheumatic Diseases

Volumn 74, Issue 6, 2015, Pages 1317-1324

  Beyer, Christian ^a   Huang, Jingang ^b   Beer, Jürgen ^c   Zhang, Yun ^d   Palumbo Zerr, Katrin ^a   Zerr, Pawel ^a   Distler, Alfiya ^a   Dees, Clara ^a   Maier, Christiane ^a   Munoz, Louis ^a   Krönke, Gerhard ^a   Uderhardt, Stefan ^a   Distler, Oliver ^b   Jones, Simon ^c   Rose John, Stefan ^d   Oravecz, Tamas ^e   Schett, Georg ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF KIEL   (Germany)

^e LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; COLLAGEN; INTERLEUKIN 6; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; ANTINEOPLASTIC ANTIBIOTIC; FLUORINATED HYDROCARBON; ORPHAN NUCLEAR RECEPTOR; SULFONAMIDE; TO-901317;

ABCA 1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; FIBROBLAST; GENE EXPRESSION REGULATION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; INFLAMMATORY INFILTRATE; KNOCKOUT MOUSE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; RECEPTOR UPREGULATION; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROSIS; WILD TYPE; AGONISTS; ANIMAL; CHEMICALLY INDUCED; DIFFUSE SCLERODERMA; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENETICS; METABOLISM; PATHOLOGY; SECRETION (PROCESS); SKIN; SKIN DISEASE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; DISEASE MODELS, ANIMAL; FIBROBLASTS; FIBROSIS; HUMANS; HYDROCARBONS, FLUORINATED; INTERLEUKIN-6; MACROPHAGES; MICE; MICE, KNOCKOUT; ORPHAN NUCLEAR RECEPTORS; SCLERODERMA, DIFFUSE; SKIN; SKIN DISEASES; SULFONAMIDES;

EID: 84934972568     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204401     Document Type: Article

References (45)

1. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18:1028-40.
2. Beyer C, Distler O, Distler JH. Innovative antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol 2012;24:274-80.
3. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
4. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
5. Zhang Y, Breevoort SR, Angdisen J, et al. Liver LXRalpha expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J Clin Invest 2012;122:1688-99.
6. Korach-Andre M, Archer A, Barros RP, et al. Both liver-X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity. Proc Natl Acad Sci USA 2011;108:403-8.
7. Stenson BM, Ryden M, Venteclef N, et al. Liver X receptor (LXR) regulates human adipocyte lipolysis. J Biol Chem 2011;286:370-9.
8. Kleyer A, Scholtysek C, Bottesch E, et al. Liver X receptors orchestrate osteoblast/ osteoclast crosstalk and counteract pathologic bone loss. J Bone Miner Res 2012;27:2442-51.
9. Asquith DL, Ballantine LE, Nijjar JS, et al. The liver X receptor pathway is highly upregulated in rheumatoid arthritis synovial macrophages and potentiates TLR-driven cytokine release. Ann Rheum Dis 2013;72:2024-31.
10. Asquith DL, Miller AM, Reilly J, et al. Simultaneous activation of the liver X receptors (LXRalpha and LXRbeta) drives murine collagen-induced arthritis disease pathology. Ann Rheum Dis 2011;70:2225-8.
11. Asquith DL, Miller AM, Hueber AJ, et al. Liver X receptor agonism promotes articular inflammation in murine collagen-induced arthritis. Arthritis Rheum 2009;60:2655-65.
12. Park MC, Kwon YJ, Chung SJ, et al. Liver X receptor agonist prevents the evolution of collagen-induced arthritis in mice. Rheumatology (Oxford) 2010;49:882-90.
13. Chintalacharuvu SR, Sandusky GE, Burris TP, et al. Liver X receptor is a therapeutic target in collagen-induced arthritis. Arthritis Rheum 2007;56:1365-7.
14. Im SS, Osborne TF. Liver x receptors in atherosclerosis and inflammation. Circ Res 2011;108:996-1001.
15. Feig JE, Pineda-Torra I, Sanson M, et al. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest 2010;120:4415-24.
16. Laragione T, Gulko PS. Liver X receptor regulates rheumatoid arthritis fibroblast-like synoviocyte invasiveness, matrix metalloproteinase 2 activation, interleukin-6 and CXCL10. Mol Med 2012;18:1009-17.
17. Yoon CH, Kwon YJ, Lee SW, et al. Activation of liver X receptors suppresses inflammatory gene expressions and transcriptional corepressor clearance in rheumatoid arthritis fibroblast like synoviocytes. J Clin Immunol 2013;33:190-9.
18. Villablanca EJ, Raccosta L, Zhou D, et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med 2010;16:98-105.
19. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008;454:470-7.
20. Jakobsson T, Treuter E, Gustafsson JA, et al. Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol Sci 2012;33:394-404.
21. Kovaleva M, Bussmeyer I, Rabe B, et al. Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display. J Virol 2006;80:8510-20.
22. Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun 2012;3:735.
23. Dees C, Akhmetshina A, Zerr P, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011;208:961-72.
24. Beyer C, Reich N, Schindler SC, et al. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012;71:1019-26.
25. Beyer C, Skapenko A, Distler A, et al. Activation of pregnane X receptor inhibits experimental dermal fibrosis. Ann Rheum Dis 2013;72:621-5.
26. Avouac J, Furnrohr BG, Tomcik M, et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011;63:800-9.
27. Limpers A, van Royen-Kerkhof A, van Roon JA, et al. Overlapping gene expression profiles indicative of antigen processing and the interferon pathway characterize inflammatory fibrotic skin diseases. Expert Rev Clin Immunol 2014;10:231-41.
28. Beyer C, Schett G, Distler O, et al. Animal models in systemic sclerosis: prospects and limitations. Arthritis Rheum 2010;62:2831-44.
29. Hazra S, Rasheed A, Bhatwadekar A, et al. Liver X receptor modulates diabetic retinopathy outcome in a mouse model of streptozotocin-induced diabetes. Diabetes 2012;61:3270-9.
30. Tachibana H, Ogawa D, Matsushita Y, et al. Activation of liver X receptor inhibits osteopontin and ameliorates diabetic nephropathy. J Am Soc Nephrol 2012;23:1835-46.
31. Uppal H, Saini SP, Moschetta A, et al. Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology 2007;45:422-32.
32. Beaven SW, Wroblewski K, Wang J, et al. Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology 2011;140:1052-62.
33. Christmann RB, Lafyatis R. The cytokine language of monocytes and macrophages in systemic sclerosis. Arthritis Res Ther 2010;12:146.
34. van Bon L, Cossu M, Radstake TR. An update on an immune system that goes awry in systemic sclerosis. Curr Opin Rheumatol 2011;23:505-10.
35. Czirjak L, Danko K, Zeher M, et al. Function of monocytes in patients with systemic sclerosis. Acta Med Hung 1988;45:53-61.
36. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013;496:445-55.
37. White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 1996;22:695-708.
38. Kraling BM, Maul GG, Jimenez SA. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995;63:48-56.
39. Higashi-Kuwata N, Jinnin M, Makino T, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 2010;12:R128.
40. O'Reilly S, Ciechomska M, Cant R, et al. Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev 2012;23:99-107.
41. De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013;40:435-46.
42. Jurisic Z, Martinovic-Kaliterna D, Marasovic-Krstulovic D, et al. Relationship between interleukin-6 and cardiac involvement in systemic sclerosis. Rheumatology (Oxford) 2013;52:1298-302.
43. Khan K, Xu S, Nihtyanova S, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 2012;71:1235-42.
44. Pendergrass SA, Lemaire R, Francis IP, et al. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 2012;132:1363-73.
45. Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 2008;3:e2696.